{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"7.3","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"Progression is defined as greater than 25% increase in enhancing tumor or the appearance of new lesions in the brain, eye, or the appearance of a new positive cerebrospinal fluid (CSF) cytology. The patient may be neurologically stable or worse and on stable or increasing doses of corticosteroid. Progression-free survival time is defined as time from registration to the date of progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. (Please note that this outcome measure is considered a secondary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. )","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase I: Temozolomide 100mg and Phase II: Temozolomide 100 mg","id":"OG000","title":"Combined Temozolomide 100mg Arms"}],"paramType":"MEDIAN","populationDescription":"Eligible patients on Temozolomide 100 mg arms who started study treatment","reportingStatus":"POSTED","timeFrame":"Analysis occured after all patients have been on study for 2 years. Maximum follow-up at time of analysis was 8.5 years.","title":"Phase II: Progression-free Survival (Including Phase I Patients at Same Dose)","type":"SECONDARY","unitOfMeasure":"years"}